StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT – Free Report) in a research note published on Monday morning. The firm issued a hold rating on the stock.
Separately, HC Wainwright reduced their target price on DBV Technologies from $20.00 to $10.00 and set a buy rating for the company in a report on Wednesday, May 8th.
Read Our Latest Research Report on DBVT
DBV Technologies Stock Performance
DBV Technologies (NASDAQ:DBVT – Get Free Report) last released its earnings results on Tuesday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.16. The company had revenue of $1.41 million during the quarter, compared to analyst estimates of $3.20 million. DBV Technologies had a negative return on equity of 56.76% and a negative net margin of 530.89%. As a group, research analysts forecast that DBV Technologies will post -1.22 EPS for the current fiscal year.
Institutional Trading of DBV Technologies
A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. boosted its holdings in shares of DBV Technologies S.A. (NASDAQ:DBVT – Free Report) by 6.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,568,909 shares of the company’s stock after buying an additional 327,345 shares during the quarter. DBV Technologies comprises 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th biggest holding. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 as of its most recent SEC filing. Institutional investors and hedge funds own 71.74% of the company’s stock.
About DBV Technologies
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Featured Stories
- Five stocks we like better than DBV Technologies
- What is the FTSE 100 index?
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- What is the Hang Seng index?
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.